Graft source determines human hematopoietic progenitor distribution pattern within the CD34+ compartment

Bone Marrow Transplantation

Volumn 46, Issue 5, 2011, Pages 650-658

  Arber, C ^a,b   Halter, J ^a   Stern, M ^a   Rovo A ^a   Gratwohl, A ^a   Tichelli, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

allogeneic hematopoietic cell transplantation; common myeloid progenitors; donor age; engraftment; graft composition; human hematopoietic stem cells

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL; BLOOD DONOR; BONE MARROW CELL; CD34+ CELL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MYELOID PROGENITOR CELL; NEUTROPHIL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETICULOCYTE; SCHOOL CHILD; THROMBOCYTE; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIGENS, CD34; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CELL COUNT; ERYTHROID PRECURSOR CELLS; FETAL BLOOD; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS;

EID: 79955888916     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.193     Document Type: Article

References (25)

1. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839-845. (Pubitemid 36675738)
2. Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114: 2606-2616.
3. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
4. Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl- Goldstein KE, Johnston LJ et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigenidentical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33: 279-285. (Pubitemid 40261309)
5. Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449-457. (Pubitemid 351372753)
6. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181. (Pubitemid 32064138)
7. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759-806. (Pubitemid 37174547)
8. Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 2008; 112: 3543-3553.
9. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006; 24: 287-320.
10. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 2804-2808.
11. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 2002; 99: 11872-11877. (Pubitemid 34994491)
12. Hao QL, Zhu J, Price MA, Payne KJ, Barsky LW, Crooks GM. Identification of a novel, human multilymphoid progenitor in cord blood. Blood 2001; 97: 3683-3690.
13. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3: 459-473.
14. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008; 180: 7358-7367.
15. Na Nakorn T, Traver D, Weissman IL, Akashi K. Myeloerythroid- restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest 2002; 109: 1579-1585. (Pubitemid 34663520)
16. Arber C, Bitmansour A, Shashidhar S, Wang S, Tseng B, Brown JM. Protection against lethal Aspergillus fumigatus infection in mice by allogeneic myeloid progenitors is not major histocompatibility complex restricted. J Infect Dis 2005; 192: 1666-1671. (Pubitemid 41504705)
17. Arber C, BitMansour A, Sparer TE, Higgins JP, Mocarski ES, Weissman IL et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2003; 102: 421-428. (Pubitemid 36841955)
18. Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA 2005; 102: 9194-9199. (Pubitemid 40923540)
19. Beerman I, Bhattacharya D, Zandi S, Sigvardsson M, Weissman IL, Bryder D et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA 2010; 107: 5465-5470.
20. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
21. d'Onofrio G, Tichelli A, Foures C, Theodorsen L. Indicators of haematopoietic recovery after bone marrow transplantation: the role of reticulocyte measurements. Clin Lab Haematol 1996; 18(Suppl 1): 45-53.
22. Imamura R, Miyamoto T, Yoshimoto G, Kamezaki K, Ishikawa F, Henzan H et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol 2005; 175: 2647-2654. (Pubitemid 41113880)
23. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-880. (Pubitemid 37369264)
24. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
25. Bautista G, Cabrera JR, Regidor C, Fores R, Garcia-Marco JA, Ojeda E et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a thirdparty donor. Bone Marrow Transplant 2009; 43: 365-373.